{
    "clinical_study": {
        "@rank": "77162", 
        "acronym": "CELIM2", 
        "arm_group": [
            {
                "arm_group_label": "Cetuximab/FOLFIRI", 
                "arm_group_type": "Active Comparator", 
                "description": "Cetuximab 250 mg/m\u00b2 (1 h) weekly Irinotecan 180 mg/m\u00b2 (1 h)*, d-l Folinic acid 400 mg/m\u00b2 (2 h), 5-FU 400 mg/m\u00b2 (Bolus), 5-FU 2400 mg/m\u00b2 (46 h) every 2 weeks\n*reduced in UGT1A1 7/7 patients"
            }, 
            {
                "arm_group_label": "Cetuximab/FOLFOXIRI", 
                "arm_group_type": "Experimental", 
                "description": "Cetuximab 250 mg/m\u00b2 (1 h) weekly Irinotecan 125 mg/m\u00b2 (1 h),* Oxaliplatin 85 mg/m\u00b2 (2 h), d-l Folinic acid 400 mg/m\u00b2 (2 h), 5-FU 3200 mg/m\u00b2 (46 h) every 2 weeks\n*reduced in UGT1A1 7/7 patients"
            }, 
            {
                "arm_group_label": "FOLFOXIRI", 
                "arm_group_type": "Active Comparator", 
                "description": "Irinotecan 165 mg/m\u00b2 (1 h)*, Oxaliplatin 85 mg/m\u00b2 (2 h), d-l Folinic acid 400 mg/m\u00b2 (2 h), 5-FU 3200 mg/m\u00b2 (46 h) every 2 weeks\n*reduced in UGT1A1 7/7 patients"
            }, 
            {
                "arm_group_label": "Bevacizumab/FOLFOXIRI", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m\u00b2 (1 h),* Oxaliplatin 85 mg/m\u00b2 (2 h), d-l Folinic acid 400 mg/m\u00b2 (2 h), 5-FU 3200 mg/m\u00b2 (46 h) every 2 weeks\n*reduced in UGT1A1 7/7 patients"
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized phase II trial to demonstrate efficacy of neoadjuvant treatment of patients with\n      non-resectable liver metastases with:\n\n        -  Cetuximab/FOLFOXIRI compared to cetuximab/FOLFIRI in patients with k-ras/b-raf wild\n           type tumours and\n\n        -  Bevacizumab/FOLFOXIRI compared to FOLFOXIRI in patients with k-ras mutant tumours with\n           regard to response rates and rate of patients who had a R0 resection of all lesions and\n           are disease free for at least 6 months (secondary aim)."
        }, 
        "brief_title": "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases", 
        "completion_date": {
            "#text": "July 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with liver metastases from colorectal and without known extrahepatic metastases\n      will be screened for this study. During screening, tumour blocks and blood samples will be\n      sent for central diagnostic of k-ras/b-raf and UGT1A1 status. B-raf mutant patients are not\n      treated within the trial.\n\n      Patients receive chemotherapy according to the allocation and are re-evaluated for\n      resectability every 8 weeks for a maximum of 6 months. Resectable patients will be resected\n      and receive an adjuvant treatment to complete 12 cycles. In circumstances detailed in the\n      protocol, a second resection is allowed within the study.\n\n      Patients will be randomized using a web-based computer system that allows randomization if\n      the key basic characteristics are entered.\n\n      Patients with k-ras and b-raf wild-type tumours will be randomized to receive:\n\n        -  Cetuximab/FOLFIRI or\n\n        -  Cetuximab/FOLFOXIRI\n\n      Patients with k-ras mutations will be randomized to receive:\n\n        -  FOLFOXIRI or\n\n        -  FOLFOXIRI/bevacizumab\n\n      Chemotherapy doses are adjusted to the risk of toxicity in all treatment arms.\n\n      Stratification will be performed according to:\n\n        -  Number of metastases (< 5 vs. \u2265 5 metastases)\n\n        -  Primary tumour in situ\n\n        -  Centre\n\n      For dose reductions and conditions to continue please refer to the full protocol. All drugs\n      are used within the label and approved doses.\n\n      Patients are evaluated for response by the same imaging technique as at baseline every 8\n      weeks. The findings will be discussed for resectability within two weeks after tumour\n      assessment in a local multidisciplinary team.\n\n      Technically resectable patients should be offered liver resection. The treatment will\n      continue until liver resection or for a maximum of six months (12 cycles).\n\n      After liver resection, an adjuvant treatment is recommended with the same schedule as\n      preoperatively, for a maximum combined pre- and postoperative treatment of 12 cycles. If\n      less than three postoperative cycles remain, no postoperative treatment will be started.\n\n      After resection, patients will be followed up for 5 years after randomization. This includes\n\n        -  imaging and clinical investigation every three months for the first 2 years, then every\n           six months (patients without tumour progression / recurrence)\n\n        -  survival status and surgical/medical treatment every three months for the first 2 years\n           and then every six months (all patients)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Non-resectable, histologically confirmed, synchronous or metachronous colorectal\n             liver metastases.\n\n          2. Non-resectability will be documented by a local multidisciplinary tumour board with\n             participation of a surgeon experienced in liver surgery. Patients can be enrolled if\n             they\n\n             a) are technically non-resectable (locally determined by a multidisciplinary team\n             discussion based on remaining functional liver tissue after resection, i.e.\n\n             i) involvement of both portal veins, all hepatic veins, portal vein of the liver lobe\n             and hepatic veins draining the segments of the other liver lobe, or ii) other reasons\n             for less than 30% remaining functional liver tissue after resection) and / or b) have\n             \u2265 5 liver metastases and / or c) are regarded as non-resectable for other reasons\n             (description necessary)\n\n          3. Patients with simultaneous liver metastases are eligible,\n\n               1. if the primary tumour was resected at least 1 month prior to chemotherapy or\n\n               2. all of the following conditions apply:\n\n             i) the primary tumour is clearly resectable, ii) no radiation therapy is planned,\n             iii) liver resection is planned before resection of the primary or at the same\n             operation as the resection of the primary, iv) no two-stage liver resection is\n             planned, and v) all efforts were made to exclude additional distant metastases.\n\n          4. WHO PS \u2264 1\n\n          5. Written informed consent\n\n          6. Adequate bone marrow function, liver function (neutrophils > 1.5 x 109/l; platelets >\n             100 x 109/l; haemoglobin > 5.0 mmol/l [8.0 g/dl]; bilirubin \u2264 ULN or \u2264 1.5 x ULN and\n             not increasing more than 25 % within the last 4 weeks; SGOT and SGPT < 5 x UNL)\n\n          7. Age \u2265 18 years\n\n        Exclusion Criteria:\n\n          1. Any evidence of extrahepatic metastases, distant lymph node metastases and primary\n             tumour recurrence\n\n          2. Patients with b-raf mutations\n\n          3. Prior systemic antitumour therapy with anti- EGFR-, antiangiogenic drugs or with\n             chemotherapy (except adjuvant chemotherapy for stage II / III with an interval of \u2265 6\n             months or in combination with radiation as radio sensitizer)\n\n          4. Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic\n             interventions or venous port implantation) \u2264 4 weeks before study entry\n\n          5. Renal insufficiency with serum creatinine \u2265 1.5 x UNL. If serum creatinine is between\n             1.0 and 1.5 x UNL, the creatinine clearance according to the Cockroft-Gault formula\n             should be \u2265 60 ml/min\n\n          6. Hypertension with an arterial blood pressure > 150/90 mmHg\n\n          7. Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or\n             IV, unstable angina pectoris, history of myocardial infarction within the last 12\n             months, significant arrhythmias\n\n          8. Known proteinuria > 1 g/day (to be tested if proteinuria more than 1+ in the urinary\n             dipstick analysis)\n\n          9. Peripheral neuropathy > CTC grade I\n\n         10. Concurrent systemic immune therapy, chemotherapy, hormone therapy, or patients\n             receiving immune suppressive treatment (i.e. for transplantation, severe\n             rheumatologic disease)\n\n         11. Participation in clinical trials with investigational agents within 30 days before\n             start of the treatment in study\n\n         12. Active treatment of\n\n               1. peptic ulcers or bleeding erosive esophagitis / gastritis within 3 months before\n                  study\n\n               2. stroke, transient ischemic attack or symptomatic pulmonary embolism within 6\n                  months before study\n\n               3. deep vein thrombosis within 4 weeks before study\n\n         13. Inflammatory bowel disease\n\n         14. History of other malignancies, from which the patient is not 5 years disease free,\n             with the exception of colorectal cancer, or adequately treated basal cell or squamous\n             cell carcinoma of skin or in-situ cervical cancer within 5 years before study\n\n         15. History of brain metastases\n\n         16. History of severe psychiatric illness\n\n         17. Active drug- or alcohol abuse\n\n         18. Known hepatitis B or C or HIV infection\n\n         19. Breast- feeding or pregnant women\n\n         20. Lack of effective contraception (for male and female patients, during study until 6\n             months after end of treatment)\n\n         21. Known intolerance to one of the following drugs: cetuximab, bevacizumab, oxaliplatin,\n             irinotecan, 5-FU, folinic acid"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "256", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802645", 
            "org_study_id": "TUD-CELIM2-050", 
            "secondary_id": "2011-003288-31"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cetuximab/FOLFIRI", 
                    "Cetuximab/FOLFOXIRI"
                ], 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": "Bevacizumab/FOLFOXIRI", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": [
                    "Cetuximab/FOLFIRI", 
                    "Cetuximab/FOLFOXIRI", 
                    "FOLFOXIRI", 
                    "Bevacizumab/FOLFOXIRI"
                ], 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": "Campto"
            }, 
            {
                "arm_group_label": [
                    "Cetuximab/FOLFOXIRI", 
                    "FOLFOXIRI", 
                    "Bevacizumab/FOLFOXIRI"
                ], 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "Eloxatin"
            }, 
            {
                "arm_group_label": [
                    "Cetuximab/FOLFIRI", 
                    "Cetuximab/FOLFOXIRI", 
                    "FOLFOXIRI", 
                    "Bevacizumab/FOLFOXIRI"
                ], 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "5-Fluorouracil"
            }, 
            {
                "arm_group_label": [
                    "Cetuximab/FOLFIRI", 
                    "Cetuximab/FOLFOXIRI", 
                    "FOLFOXIRI", 
                    "Bevacizumab/FOLFOXIRI"
                ], 
                "intervention_name": "Folinic Acid", 
                "intervention_type": "Drug", 
                "other_name": "Leukovorin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Bevacizumab", 
                "Cetuximab", 
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "neoadjuvant", 
            "cetuximab", 
            "irinotecan", 
            "bevacizumab", 
            "oxaliplatin", 
            "5-FU", 
            "Resection", 
            "colorectal liver metastases", 
            "liver resection", 
            "Chemotherapy", 
            "k-ras", 
            "non-resectable"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "chirurgie@ukaachen.de", 
                    "last_name": "Ulf-Peter Neumann, Prof. Dr.", 
                    "phone": "0241 8085660"
                }, 
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "52074"
                    }, 
                    "name": "Universit\u00e4tsklinikum der RWTH Aachen"
                }, 
                "investigator": {
                    "last_name": "Ulf-Peter Neumann, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "daniel.seehofer@charite.de", 
                    "last_name": "Daniel Seehofer, PD Dr. med.", 
                    "phone": "030/ 450 652062"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Charit\u00e9 Campus Virchow"
                }, 
                "investigator": {
                    "last_name": "Daniel Seehofer, PD Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Gunnar.Folprecht@uniklinikum-dresden.de", 
                    "last_name": "Gunnar Folprecht, PD Dr. med.", 
                    "phone": "+49 351 458 4794"
                }, 
                "contact_backup": {
                    "email": "olga.schubert@uniklinikum-dresden.de", 
                    "last_name": "Olga Schubert", 
                    "phone": "+49 351 7965620"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Universit\u00e4tsklinikum Carl Gustav Carus"
                }, 
                "investigator": {
                    "last_name": "Gunnar Folprecht, PD Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tliersch@chirurgie-goettingen.de", 
                    "last_name": "Torsten Liersch, PD Dr. med.", 
                    "phone": "0551/ 398323"
                }, 
                "facility": {
                    "address": {
                        "city": "G\u00f6ttingen", 
                        "country": "Germany", 
                        "zip": "37075"
                    }, 
                    "name": "Universit\u00e4tsmedizin G\u00f6ttingen"
                }, 
                "investigator": {
                    "last_name": "Torsten Liersch, PD Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "d.arnold@uke.de", 
                    "last_name": "Dirk Arnold, Prof. Dr.", 
                    "phone": "040/ 7410 55489"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }, 
                    "name": "Universit\u00e4tsklinikum Hamburg-Eppendorf"
                }, 
                "investigator": {
                    "last_name": "Dirk Arnold, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Florian.Lordick@medizin.uni-leipzig.de", 
                    "last_name": "Florian Lordick, Pr.", 
                    "phone": "+49 341 97 12560"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }, 
                    "name": "University hospital Leipzig"
                }, 
                "investigator": {
                    "last_name": "Florian Lordick, Pr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "markus.moehler@unimedizin-mainz.de", 
                    "last_name": "Markus M\u00f6hler, PD Dr.", 
                    "phone": "+49 6131 17 6863"
                }, 
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55131"
                    }, 
                    "name": "Johannes-Gutenberg-Universit\u00e4t"
                }, 
                "investigator": {
                    "last_name": "Markus M\u00f6hler, PD Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "onkologie@klinikum-oldenburg.de", 
                    "last_name": "Claus-Henning K\u00f6hne, Prof. Dr.", 
                    "phone": "+49 441 403-2610"
                }, 
                "facility": {
                    "address": {
                        "city": "Oldenburg", 
                        "country": "Germany", 
                        "zip": "26133"
                    }, 
                    "name": "Klinikum Oldenburg GmbH"
                }, 
                "investigator": {
                    "last_name": "Claus-Henning K\u00f6hne, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kunzmann_v@medizin.uni-wuerzburg.de", 
                    "last_name": "Volker Kunzmann, PD Dr. med.", 
                    "phone": "0931/20140746"
                }, 
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97080"
                    }, 
                    "name": "Universit\u00e4tsklinikum W\u00fcrzburg"
                }, 
                "investigator": {
                    "last_name": "Volker Kunzmann, PD Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.", 
        "other_outcome": [
            {
                "description": "Resection rate, defined as patients with microscopically complete (R0) resection (ITT- population)", 
                "measure": "R0 resection rate", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year after randomization"
            }, 
            {
                "description": "Rate of liver resection with macroscopically tumour free margins and/or RFA (all patients with R0 or R1 resection and/or complete RFA of all lesion, ITT- population)", 
                "measure": "Resection rate", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year after randomization"
            }, 
            {
                "description": "Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years after randomization"
            }, 
            {
                "description": "Disease free survival after resection (Medium, Kaplan-Meier-estimation, resected patients)", 
                "measure": "Disease free survival after resection", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years after resection"
            }, 
            {
                "description": "Overall survival (Kaplan-Meier-estimation, ITT- population)", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 year after randomization"
            }, 
            {
                "description": "Toxicity according to NCI-CTC criteria v. 4.0 Perioperative toxicity according to Clavien", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year after randomization"
            }, 
            {
                "description": "Pathological response in the resected tumour tissue", 
                "measure": "Pathological response", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year after randomization"
            }, 
            {
                "description": "Evaluation of molecular predictive markers for response (i.e. other mutations in EGFR signalling pathway, EGFR ligands) and toxicity", 
                "measure": "Molecular markers", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year after randomization"
            }
        ], 
        "overall_contact": {
            "email": "Gunnar.Folprecht@uniklinikum-dresden.de", 
            "last_name": "Gunnar Folprecht, PD Dr.", 
            "phone": "+49 351 458 4794"
        }, 
        "overall_contact_backup": {
            "email": "Olga.Schubert@uniklinikum-dresden.de", 
            "last_name": "Olga Schubert", 
            "phone": "+49 351 79 656 20"
        }, 
        "overall_official": {
            "affiliation": "University hospital \"Carl Gustav Carus\" Dresden", 
            "last_name": "Gunnar Folprecht, PD Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of patients with partial or complete response according to modified RECIST criteria.", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Rate of patients who had a R0 resection of all lesions and are disease free for at least 6 months in the ITT population.", 
            "measure": "Rate of resected patients without early relaps", 
            "safety_issue": "No", 
            "time_frame": "6 months after resection"
        }, 
        "source": "Technische Universit\u00e4t Dresden", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Technische Universit\u00e4t Dresden", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}